Hyperlipidemia: Difference between revisions

Jump to navigation Jump to search
Line 28: Line 28:
[[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | Recommendations for drug therapy]] | [[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | [[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]]
[[Hyperlipidemia NCEP recommendations for drug therapy of high-risk hyperlipidemia in children and adolescents | Recommendations for drug therapy]] | [[Hyperlipidemia statins in children and adolescents with hyperlipidemia | Statins]] | [[Hyperlipidemia NCEP guidelines for adjuvant therapies in children and adolescents | Adjuvant therapies]]


'''Pharmacotherapy'''
[[Hypertriglyceridemia medical therapy | Pharmacotherapy]]
 
[[Statins]] | [[Niacin]] | [[Fibrate]] | [[Omega-3 fatty acids]]
[[Statins]] | [[Niacin]] | [[Fibrate]] | [[Omega-3 fatty acids]]



Revision as of 14:23, 20 November 2011